Telix Pharmaceuticals Limited Increase Decrease Through Financing Cash Flows Liabilities Arising From Financing Activities
Telix Pharmaceuticals Limited (TLPPF) reported Increase Decrease Through Financing Cash Flows Liabilities Arising From Financing Activities of -$19.27 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-02-20.
Financial Statements › Cash Flow › Operating Activities
ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities · last filed 2026-02-20
AUD
| Period end | Increase Decrease Through Financing Cash Flows Liabilities Arising From Financing Activities 12 month |
|---|---|
| 2024-12-31 | 637.71M AUD 20-F · filed 2025-02-24 |
| 2023-12-31 | 2.90M AUD 20-F · filed 2025-02-24 |
USD
| Period end | Increase Decrease Through Financing Cash Flows Liabilities Arising From Financing Activities 12 month |
|---|---|
| 2025-12-31 | -$19.27M 20-F · filed 2026-02-20 |
| 2024-12-31 | $415.45M 20-F · filed 2026-02-20 |